Bacteria injected into tumors: a new hope for cancer patients?

NCT ID NCT07556276

Recruiting now Disease control Sponsor: The Second Hospital of Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing whether a specially designed bacteria, CMTS1215, can safely shrink solid tumors. About 20 adults with advanced solid tumors who have no other treatment options will receive the bacteria directly into their tumor or through a vein. The main goals are to check safety and see if tumors respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CMTS1215 (oncolytic bacteria)
What this could lead to: If it works, this could point toward a new treatment option for people with solid tumors who have run out of standard therapies.
What could go wrong: This is a very early, small trial (20 people) testing safety first. The bacteria may not shrink tumors, and side effects are unknown. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Department of Microbiota Medicine & Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.